Abnormal cortisol awakening response predicts worse cognitive function in patients with first-episode psychosis

M. Aas[1], **P. Dazzan**[2,3], **V. Mondelli**[1], **T. Toulopoulou**[2], **A. Reichenberg**[2,3], **M. Di Forti**[2,3], **H. L. Fisher**[4], **R. Handley**[2], **N. Hepgul**[1], **T. Marques**[2], **A. Miorelli**[2], **H. Taylor**[1,2], **M. Russo**[2], **B. Wiffen**[2], **A. Papadopoulos**[5], **K. J. Aitchison**[4], **C. Morgan**[3,6], **R. M. Murray**[2,3], and **C. M. Pariante**[1,3,*]

[1]Department of Psychological Medicine, Institute of Psychiatry, King's College London, UK

[2]Department of Psychosis Studies, Institute of Psychiatry, King's College London, UK

[3]NIHR Biomedical Research Centre for Mental Health, South London and Maudsley NHS Foundation Trust and Institute of Psychiatry, King's College London, UK

[4]MRC Social Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, UK

[5]Affective Disorder Unit, South London and Maudsley NHS Trust, London, UK

[6]Department of Health Services and Population Research, Institute of Psychiatry, King's College London, UK

Abstract

Background—Cognitive impairment, particularly in memory and executive function, is a core feature of psychosis. Moreover, psychosis is characterized by a more prominent history of stress exposure, and by dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis. In turn, stress exposure and abnormal levels of the main HPA axis hormone cortisol are associated with cognitive impairments in a variety of clinical and experimental samples; however, this association has never been examined in first-episode psychosis (FEP).

Method—In this study, 30 FEP patients and 26 controls completed assessment of the HPA axis (cortisol awakening response and cortisol levels during the day), perceived stress, recent life events, history of childhood trauma, and cognitive function. The neuropsychological battery comprised general cognitive function, verbal and non-verbal memory, executive function, perception, visuospatial abilities, processing speed, and general knowledge.

Results—Patients performed significantly worse on all cognitive domains compared to controls. In patients only, a more blunted cortisol awakening response (that is, more abnormal) was associated with a more severe deficit in verbal memory and processing speed. In controls only, higher levels of perceived stress and more recent life events were associated with a worse performance in executive function and perception and visuospatial abilities.

Conclusions—These data support a role for the HPA axis, as measured by cortisol awakening response, in modulating cognitive function in patients with psychosis; however, this association

does not seem to be related to the increased exposure to psychosocial stressors described in these patients.

Introduction

The majority of patients with psychosis, even at the time of their first episode, function at a cognitive level at least one standard deviation below that of healthy comparison groups (Reichenberg & Harvey, 2007; Zanelli *et al.* 2010), with specific domains showing greater dysfunction, such as episodic memory, working memory and executive function (Flashman & Green, 2004; Reichenberg & Harvey, 2007). Patients with psychosis also show a more prominent history of stress exposure, such as increased rates of a history of childhood trauma (Read *et al.* 2005; Fisher *et al.* 2009a), increased distress and inability to handle life events (Horan *et al.* 2005), and increased number of adverse life events (Bebbington *et al.* 2004). However, whether or not there is an association between biological and psychosocial markers of stress and cognitive function in psychosis is unclear.

We have recently described, in a large group of first-episode psychosis (FEP) patients, increased levels of perceived stress and increased exposure to recent life events and childhood trauma, together with a specific abnormality in the hypothalamic–pituitary–adrenal (HPA) axis activity, namely, a blunted cortisol awakening response in the context of increased cortisol levels during the day (Mondelli *et al.* 2010a). These data confirm previous findings of increased cortisol levels, increased pituitary volume, and glucocorticoid (GC) resistance (that is, a decreased HPA axis suppression response to the synthetic GC dexamethasone, in the dexamethasone suppression test) in patients with FEP (Pariante *et al.* 2004, 2005; Ryan *et al.* 2004; Ceskova *et al.* 2006) and affective psychosis (Belanoff *et al.* 2001). It is particularly important to emphasize the uniqueness of the HPA axis abnormalities described in FEP: blunted cortisol awakening response in the context of increased cortisol levels during the day and GC resistance. These abnormalities are different from those described in post-traumatic stress disorder (PTSD) (blunted cortisol awakening response in the context of decreased cortisol levels during the day and GC hypersensitivity, that is, an enhanced HPA suppressive response to dexamethasone; Heim & Nemeroff, 2002; Yehuda, 2005), and also from those described in depression (increased cortisol awakening response in the context of increased cortisol levels during the day and GC resistance; Pariante & Lightman, 2008; Cowen, 2010). Therefore, the biological abnormalities described in the stress response of patients with FEP cannot be considered simply a consequence of distress or of co-morbid mental disorders, and indeed reflect a specific stress signature. Taken together, these lines of evidence strongly support the notion that an abnormal stress response, perhaps linked to the psychosocial environment, participates to the predisposition to psychosis (Belanoff *et al.* 2001; Myin-Germeys *et al.* 2001, 2005; Halari *et al.* 2004; Garner *et al.* 2005; Gomez *et al.* 2006).

It is well known that stress and GC hormones can act on the brain (particularly on the hippocampus), leading to cognitive impairment. For example, disorders characterized by increased stress exposure such as depression, PTSD and chronic fatigue syndrome, also show cognitive impairment, particularly in memory and executive function (Porter *et al.* 2003; Sandstrom *et al.* 2005; Weber *et al.* 2005). Moreover, animals or healthy humans treated with endogenous of synthetic GCs show cognitive impairment, again predominantly in memory and executive domains (McAllister-Williams & Rugg, 2002; Hsu *et al.* 2003; Wolf, 2003). Elderly subjects with long-term stress exposure also show similar cognitive

abnormalities (Lupien *et al.* 2005, 2007). However, notwithstanding the obvious potential association between high levels of stress, HPA axis abnormalities and cognitive function in patients with a psychotic disorder, the very few studies conducted until now (all in patients with an established diagnosis and a long duration of illness) have led to inconclusive results.

Over two decades have passed since the first study investigating the HPA axis and cognitive abnormalities in schizophrenia was published (Saffer *et al.* 1985), showing a strong correlation between dexamethasone non-suppression and worse cognitive performance, but only in patients with predominantly negative symptoms. Walder *et al.* (2000) evaluated patients with schizophrenia, schizo-affective disorder, other psychiatric disorders and healthy controls, and found, in the entire sample, that cortisol levels were negative correlated with performance in memory and executive tasks. The study by Halari *et al.* (2004) also demonstrated a relationship between increased cortisol levels and decreased performance on processing speed in 20 male patients with chronic schizophrenia. Similar findings of a relationship between increased cortisol during the day and cognitive impairment in patients with psychotic depression have also been reported in the literature (Belanoff *et al.* 2001). There are, of course, several confounders in evaluating the HPA axis and cognition in patients with an established diagnosis of schizophrenia, including the effects of age and of many years of continuous illness, antipsychotic treatment and repeated relapses. To date, there are no studies that have investigated the HPA axis together with cognition in FEP, which is the aim of this paper. Our primary hypothesis was that an abnormal HPA axis function, as indicated by a blunted cortisol awakening response and increased cortisol levels during the day, would be associated with a worse cognitive performance in FEP patients.

It is also of interest that, to our knowledge, no studies have directly related cognitive performance to psychosocial measures of stress in FEP. Previous published papers show a link between psychosocial stress and changes in the structure of important brain regions associated with cognitive function, such as the hippocampus (Szeszko *et al.* 2006; Gianaros *et al.* 2007). Moreover, several studies show an association between a history of childhood trauma and poorer scores on several cognitive tasks when assessed in adulthood (Perez & Widom, 1994). Only two studies have investigated cognition and early trauma in people with psychosis, both in individuals with an established diagnosis and a long duration of illness. Lysaker *et al.* (2001) found that patients with childhood sexual abuse had impaired processing speed, working memory and executive function compared with patients without abuse. Schenkel *et al.* (2005) found that patients with a history of childhood trauma showed a decreased score on learning and visual context processing compared to non-abused patients. To our knowledge, no studies have investigated psychosocial stress together with cognitive performance in FEP, or other aspects of psychosocial stress besides childhood trauma. Therefore, our secondary hypothesis is that increased exposure to psychosocial stressors, as indicated by increased levels of perceived stress, more recent life events or a history of childhood trauma, is associated with a worse cognitive performance in FEP.

The patients described in this paper belong to a larger group described previously, as mentioned earlier (Mondelli *et al.* 2010a). This paper presents, for the first time, the cognitive data in this sample, together with the relationship between cognitive function and the biological and psychosocial stress measures. We also specifically investigate the effects of cannabis use, as patients with psychosis tend to have higher use of cannabis compared to the general population (Di Forti *et al.* 2009), and the literature shows an association between cannabis use and both cognitive function (Loberg & Hugdahl, 2009; Ringen *et al.* 2009) and cortisol levels (Mondelli *et al.* 2010a) in psychosis.

Method

Subjects

FEP patients were recruited in London (UK) from the South London and Maudsley (SLAM) National Health Service (NHS) Foundation Trust (boroughs of Lambeth, Southwark and Croydon), as part of the Genetic and Psychosis (GAP) study (Di Forti *et al.* 2009; Mondelli *et al.* 2010a, b). The recruitment strategy was based on contacting in-patient and out-patient services regularly, interviewing staff and reviewing clinical notes to identify all subjects aged 18–65 years who presented for the first time to these services for a functional psychotic illness (ICD-10 F10–19, excluding coding F1x.0 for Acute Intoxication; F20–29 and F30–39, psychotic codings) (WHO, 1992), as in previous similar studies in this setting (Dazzan *et al.* 2004, 2005, 2008). Patients with organic psychosis, learning disabilities, a history of traumatic brain injury, or requiring a translator because of lack of English fluency were excluded from the study. Controls were recruited from the same catchment area as the patients through advertisement in local newspapers, hospitals and job centres, and from existing volunteer databases. Controls were screened using the Psychosis Screening Questionnaire (PSQ; Bebbington & Nayani, 1995), and excluded if they met criteria for a present or past psychotic disorder. Both patients and controls were excluded if taking hormonal treatment, or if they had a diagnosis of neuroendocrine disorder (e.g. Cushing's syndrome). The study was approved by the local Ethical Committee, in accordance with the code of ethics of the World Medical Association, and written informed consent was obtained from all participants.

Thirty patients and 26 healthy age- and gender-matched controls underwent neuropsychological, clinical and endocrinological assessments, as detailed below. All assessments were conducted within 6 months of the first contact with mental health services for psychosis; the average duration of illness (defined as above) was, however, much shorter, at 41±33 days. Five of the patients were drug naïve or medication free, 22 were taking atypical antipsychotics, and three were taking typical antipsychotics; 27 patients had a diagnosis of schizophrenia or delusional disorder, and three had a diagnosis of 'other psychosis', according to DSM-IV criteria (APA, 2000). None of the subjects were taking drugs such as antidepressants or steroids, known to affect the HPA axis.

Questionnaires and clinical assessment

Sociodemographic data were collected using a modified version of the Medical Research Council (MRC) Sociodemographic Schedule. Validation of clinical diagnosis was obtained using the Operational Criteria (OPCRIT) computer program (McGuffin *et al.* 1991), by reviewing the case-notes for the month following first contact with services. The presence or absence of symptoms was measured by the OPCRIT checklist using the strict OPCRIT definitions, which has excellent agreement with the currently accepted 'gold standard' of best estimate diagnosis in similar studies (McGuffin *et al.* 1991). Inter-rater reliability between researchers for the OPCRIT was high (Cronbach's a=0.91).

We measured the perceived stress, in the previous month, using the Perceived Stress Scale (Cohen *et al.* 1983). This is a 10-item scale measuring the degree to which situations in one's life are appraised as stressful. We also collected information about stressful life events, in the previous 6 months, using the Brief Life Events Questionnaire (Brugha & Cragg, 1990). This questionnaire assesses both the number and the emotional impact of life stressors involving moderate or long-term threat. History of childhood physical abuse, sexual abuse, separation and loss was obtained with the Childhood Experience of Care and Abuse Questionnaire (CECA-Q). All trauma events used in the analyses occurred during childhood (0–11 years) (Thornberry *et al.* 2001; Widom *et al.* 2008). Psychosis patients'

responses on the CECA-Q have been demonstrated to have reasonable test–retest reliability and convergent validity (Fisher *et al.* 2009b). For the analyses, the most conservative cut-off points published by Bifulco *et al.* (2005) were used to dichotomize responses on the CECA-Q into severe and non-severe categories for each maltreatment variable.

Salivary cortisol assessment

Saliva samples were collected to measure salivary cortisol using Salivettes (Sarstedt, UK), in which saliva is absorbed in a cotton roll. Subjects were instructed to collect saliva samples by chewing the cotton roll for 2 min, immediately after awakening (0 min) and 15, 30 and 60 min after awakening, and again at 12:00 and at 20:00 hours. Test–retest analyses over two consecutive days in a subset of patients confirm reliability of these measures (Mondelli *et al.* 2010a). Saliva cortisol concentrations were determined using the 'Immulite', DPC's Immunoassay analyzer (Siemens, UK). The plasma cortisol assay of the analyser was suitably modified and then validated for these measurements; the details of the analytical procedures have also been described previously (Mondelli *et al.* 2010a, b). For our analyses, we used the Area Under the Curve (AUC) of the increase (AUCi) of cortisol levels after awakening, and the AUC of cortisol levels during the day (awakening, 12:00 and 20:00 hours), as derived from the trapezoid formula, again as described previously (Mondelli *et al.* 2010a, b).

Neuropsychological assessment

All patients and controls underwent neuropsychological assessment to assess the following six domains: (1) verbal memory; (2) non-verbal memory; (3) executive function and working memory; (4) processing speed; (5) perception and visuospatial abilities; and (6) general knowledge. Individual test scores were converted into standardized z scores based on the mean and standard deviation of test performance by the normal control group. To examine performance by domain, z scores in each domain were averaged together. Confirmatory correlational analyses were conducted to ensure that test scores within each domain shared similar variance and could therefore be considered of the same cognitive construct (Brickman *et al.* 2004). For these analyses, a Pearson correlation coefficient 0.50 was considered large enough to be considered from the same domain (Brickman *et al.* 2004); all tests within each domain met this criterion. All tests were administered and scored by specially trained research workers.

The neuropsychological battery (for each domain) was composed as follows (see also Table 2 in the Results section, and Supplementary material online). Raw data were used for all measures.

General cognitive function

Full-scale IQ was derived from the Wechsler Adult Intelligence Scale – Third Edition (WAIS-III; Wechsler, 1997a) from subtests in the neuropsychological battery. Pre-morbid IQ was obtained using the National Adult Reading Test (NART; Nelson & Willison, 1991).

Verbal memory

The Wechsler Memory Scale – Third Edition (WMS-III) was used to measure verbal memory (logical memory) at immediate and delayed (30-min delay) time points (Wechsler, 1997b).

Non-verbal memory

The WMS-III was administered to measure non-verbal memory (visual reproduction) at immediate and delayed (30-min delay) time points (Wechsler, 1997b).

Executive function and working memory

To measure executive function and working memory, we used Trail B and the Spatial Working Memory (SWM) from the Cambridge Neuropsychological Test Automated Battery (CANTAB; Gau & Shang, 2010).

Perception and visuospatial abilities

Perception and visuospatial abilities were measured using the Block Design task (Wechsler, 1997a) and the Matrix Reasoning (Wechsler, 1997a).

Processing speed

Processing speed was measured by Digit Symbol Coding from the WAIS-III (Wechsler, 1997a), and Trail A. Trail A is considered a processing speed and attention task.

General knowledge

To measure general knowledge, we used information from the WAIS-III (Wechsler, 1997a), which includes questions about geography and literature and is part of the verbal subtests of the WAIS-III.

Statistical analyses

Data were analysed using SPSS version 15.0 (SPSS Inc., USA). Continuous variables are presented as means±standard deviation. A two-tailed independent t test was used to compare means of continuous variables between patients and controls (e.g. cognitive data and biological stress measures). We also conducted analyses of variance (ANOVA) and covariance (ANCOVA), controlling for education, ethnicity and lifetime cannabis use. The χ^2 test was used to compare categorical variables (e.g. gender) between patients and controls. Z scores for individual tests were averaged to establish an overall score in each cognitive area. Cortisol awakening response was distributed normally in both patients and controls, whereas cortisol levels during the day were only distributed normally in the controls. Because of the small sample size, non-parametric Spearman's correlations were conducted when analysing cortisol levels and cognitive function. Analyses correlating individual cognitive tasks are presented with and without adjustment using Bonferroni's correction, as supplementary material online.

Results

Demographic and clinical characteristics of the sample

Sociodemographic and clinical characteristics of the sample are presented in Table 1. These characteristics are consistent with those described previously in a larger sample comprising these patients (Mondelli *et al.* 2010a). There were no differences in age or gender distribution, but the controls had a higher level of education than the patients. Trend-significant differences were found for ethnicity and cannabis use, as there were more individuals of African or Caribbean origin in the patient group (p=0.07), and more patients had a lifetime history of cannabis use (p=0.054).

Cognitive function in patients and controls

Table 2 shows the results of an ANOVA and an ANCOVA comparing patients and controls for cognitive performance on the tasks described above. Using unadjusted analyses, patients performed worse on all cognitive tests compared to controls, including current and pre-morbid IQ. Even after controlling for education, ethnicity and cannabis use, patients scored

significantly worse than the controls on the majority of the individual cognitive tasks, and especially in verbal memory tasks.

Cortisol awakening response and cognitive function

Patients had a smaller (blunted) cortisol awakening response (p=0.027) compared with controls (see Table 1). The relationship between the cortisol awakening response and cognitive tasks is shown in Table 3, using Spearman's analyses to correlate the AUCi with the z scores of the six cognitive domains. In patients, significant positive correlations were observed for the verbal memory (r=0.48, p=0.019) and processing speed (r=0.38, p=0.048) domains, and a trend-level correlation was present for the non-verbal memory domain (r=0.35, p=0.073). These data indicate that a smaller cortisol awakening response in patients (i.e. more blunted and hence more abnormal) was associated with worse performances on verbal and non-verbal memory, and also with worse processing speed. Fig. 1 shows the scatter plots of these data sets. No relationship between cortisol awakening response and cognitive domains was observed in the controls.

To corroborate these findings, we further analysed the data by dividing both patients and controls into two groups based on whether their cortisol awakening response was above or below the median of their group (see Fig. 2*a*). Within patients, the group with the cortisol awakening response below the median (i.e. more blunted and hence more abnormal) did worse on verbal memory (t=−2.50, p=0.02) and processing speed (t=−2.81, p=0.012), and, at trend significance, on perception and visuospatial abilities (t=−1.75, p=0.09). Of interest, there were no differences between the two groups of patients in terms of age (t=−0.35, p=0.7), ethnicity (χ^2=0.62, p=0.7), education (χ^2=1.71, p=0.8), diagnoses ($\chi^2 = 0.08$, p=0.8), and cannabis use (χ^2=1.5, p=0.7).

Finally, is important to mention that these data are also consistent with the correlation analyses conducted between cortisol awakening response and the individual cognitive tasks (see Supplementary online material, Table S1), with a more blunted cortisol awakening response correlating significantly with a worse performance in tasks of verbal memory (Logical Memory Immediate Thematic score, Logical Memory Delayed Recall, Logical Memory Delayed thematic score), attention and processing speed (Trail A, Digit Symbol Coding), and, at trend level, for non-verbal memory (Visual Reproduction Delayed Recall, Visual Percentage Retention); however, in controls the cortisol awakening response did not correlate with any tasks.

Cortisol during the day and cognitive function

Patients had a trend for a higher cortisol level during the day (p=0.09) compared with controls (see Table 1). No significant correlations were found when investigating the correlations between cortisol AUCs during the day and cognitive domains, in either patients or controls (Table 3). Moreover, no differences were found in cognitive function between subjects with low and high cortisol levels during the day (divided based on the sample median), in either patients or controls (see Fig. 2b).

Psychosocial stress and cognitive function

Patients had higher levels of perceived stress (p<0.001), recent stressful events (p<0.001) and childhood trauma (p=0.008) (see Table 1). In patients, we found no correlations between any of the cognitive domains and the scores at the Brief Live Events Questionnaire or the Perceived Stress Scale, or the presence or absence of a history of childhood trauma (see Table 4). However, in controls we found that higher levels of perceived stress and more recent life events were associated with a worse performance in executive function (r=−0.43, p=0.029 and r=−0.40, p=0.043 respectively) and perception and visuospatial abilities (r=

−0.55, p=0.003 and r=−0.40, p=0.045 respectively). Correlation analyses with individual tasks also confirmed these findings (see Supplementary online material, Table S2).

Discussion

In agreement with previous studies, patients with FEP in our sample showed significant cognitive deficits compared to healthy controls, in particular in verbal memory. Moreover, the deficits in verbal memory and processing speed were strongly correlated with a dysregulated HPA axis, as shown by a more blunted cortisol response to awakening. Surprisingly, cortisol levels during the day and psychosocial stressors (perceived stress, recent life events, history of childhood trauma) did not affect cognitive function in patients.

The blunted cortisol response to awakening in this sample has been described and discussed previously (Mondelli *et al.* 2010a). In the present paper, we find that a smaller (more blunted) cortisol awakening response correlates with worse verbal memory and processing speed. One possible explanation for this association is that an abnormal function of the hippocampus cortex may underlie both the cognitive and the HPA axis abnormalities. The GC receptors (GRs) and the mineralocorticoid receptors (MRs) in the hippocampus play an important regulatory role on the HPA axis, by mediating the negative feedback by circulating GCs on the HPA axis, and are also significantly involved in the learning and memory processes localized in this area (Lupien *et al.* 2005, 2007). Indeed, both bilateral and unilateral hippocampus damage are associated with an absent or blunted cortisol awakening response (Buchanan *et al.* 2004). A reduced hippocampus volume has been reported in a meta-analysis of FEP patients, with a reduction of 9% in the right hippocampus and of 10 % in the left hippocampus (Copolov *et al.* 2000). Moreover, a study of an epidemiologically based sample of FEP patients has also confirmed a decreased grey matter in the hippocampus (Morgan *et al.* 2007). However, the relationship between cortisol, stress and anatomic substrates of cognitive deficits is complex, and not all findings support this model. For example, our recent study indeed found that higher cortisol levels during the day were associated with a smaller (left) hippocampal volume in first-episode psychosis (Mondelli *et al.* 2010b), but a previous study by Gunduz-Bruce *et al.* (2007) did not find any correlations. Another, non-mutually exclusive explanation for the association between abnormal cortisol awakening response and cognitive impairment is the presence of sleep disturbance, which is often seen in patients with psychosis (Suzuki *et al.* 2009). Indeed, a smaller awakening response is observed in patients with insomnia (Backhaus *et al.* 2004), and insomnia is linked to decreased memory performance (Backhaus *et al.* 2006). Therefore, sleep disturbances in these patients may contribute to the association between abnormal cortisol awakening response and cognitive impairment.

The slightly increased cortisol levels during the day in this sample have also been described and discussed before (Mondelli *et al.* 2010a). It is of interest that a study by Lee *et al.* (2007) has shown that increased cortisol levels during the day are associated with a worse cognitive performance in a large sample of much older normal subjects (50–70 years of age). Moreover, many studies have shown that healthy participants given oral doses of cortisol or other GCs have impairment of both episodic memory and executive function (Newcomer *et al.* 1994; McAllister-Williams & Rugg, 2002; Hsu *et al.* 2003; Brunner *et al.* 2006). Moreover, patients with psychotic depression, who have increased cortisol levels in the evening and night, show impaired verbal memory when compared not only with normal controls but also with nonpsychotic depressed patients (Belanoff *et al.* 2001), and show correlations between higher cortisol levels and poorer verbal memory and processing speed (Gomez *et al.* 2006). Similar findings have been described in patients with schizophrenia (Walder *et al.* 2000; Halari *et al.* 2004) or bipolar disorder (Young *et al.* 2004). Although it is somewhat surprising that we did not find a relationship between cortisol levels during the

day and (worse) cognitive function in FEP, we should emphasize that the cortisol values in our samples were only mildly elevated. It is also of note that one study, administering GCs to patients with schizophrenia, found a lack of effects of dexamethasone on verbal memory (Newcomer *et al.* 1998). Taken together, these findings suggest that cognitive function in patients with psychosis is less sensitive to the effects of GCs than in healthy subjects, perhaps as part of a generalized 'GC resistance'; that is, resistance of the brain to the effects of GCs (Pariante & Lightman, 2008).

The mostly negative findings regarding the effects of psychosocial stressors on cognitive function in this sample should also be commented upon. Although, to our knowledge, this is the first study investigating the relationship between cognitive function and perceived stress, recent life events or childhood trauma in FEP, it is interesting that Myin-Germeys *et al.* (2002) and Morrens *et al.* (2007) also did not find any relationship between negative emotions triggered by mild stressors in daily life and cognitive function in patients with established schizophrenia. We did find evidence for impaired executive function and impaired perception and visuospatial abilities in healthy controls with higher levels of perceived stress and more recent life events, thus confirming that our measures were sensitive enough to detect an effect, if present. We have also reported previously that there is no association between these psychosocial measures of stress and HPA axis activity in this sample of FEP, although there is an association between more recent life events and increased cortisol levels in controls (Mondelli *et al.* 2010a). Taken together, these findings suggest that the abnormal HPA axis activity in these patients (and its association with impaired cognitive function) is not simply driven by the excess of psychosocial stressors before the onset of psychosis. It is also of note that two previous studies have found that a history of childhood trauma is associated with worse executive function in patients with established (not first-episode) schizophrenia/schizo-affective disorder (Lysaker *et al.* 2001; Schenkel *et al.* 2005); it is possible that the effect of childhood trauma on cognition becomes evident with the progression of the psychotic illness from first episode to chronic status.

Finally, there is an important methodological consideration that needs to be taken into account in the interpretation of our findings. Specifically, patients and controls differed on important clinical and demographic measures such as education, ethnicity, use of cannabis, and antipsychotic administration. As these factors are all associated with psychosis, obtaining controls that are matched for them is almost impossible. However, patients continue to score lower than controls in the relevant cognitive tasks even after covarying for these variables. Moreover, our main findings (the effects of cortisol awakening response on cognitive tasks in patients) are not explained by the effects of age, ethnicity, education, diagnoses, or cannabis use. Antipsychotics are also unlikely to play a role here: these findings are based on within-patients comparisons, and most patients were on antipsychotics; we have also shown previously that antipsychotic treatment does not influence the cortisol awakening response (Mondelli *et al.* 2010a). However, we cannot exclude complex interactions between these variables, leading to different appraisals of stressful situations or different biological stress responses in patients (or subgroups of patients) when compared with controls. We also acknowledge the small sample size, and replication of our findings in a larger sample is imperative.

In summary, we have demonstrated a relationship between abnormal HPA axis activity (as measured by a blunted cortisol awakening response) and impaired cognitive function in patients with FEP. Future prospective studies are needed to dissect the direction of the effects: to test whether normalization of the clinical picture with antipsychotic treatment is associated with normalization of HPA axis activity, and, if so, whether this predicts improvement in cognitive function.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

References

APA. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association; Washington, DC: 2000.

Backhaus J, Junghanns K, Born J, Hohaus K, Faasch F, Hohagen F. Impaired declarative memory consolidation during sleep in patients with primary insomnia: influence of sleep architecture and nocturnal cortisol release. Biological Psychiatry. 2006; 60:1324–1330. [PubMed: 16876140]

Backhaus J, Junghanns K, Hohagen F. Sleep disturbances are correlated with decreased morning awakening salivary cortisol. Psychoneuroendocrinology. 2004; 29:1184–1191. [PubMed: 15219642]

Bebbington P, Nayani T. The psychosis screening questionnaire. International Journal of Methods in Psychiatric Research. 1995; 5:11–19.

Bebbington PE, Bhugra D, Brugha T, Singleton N, Farrell M, Jenkins R, Lewis G, Meltzer H. Psychosis, victimisation and childhood disadvantage: evidence from the second British National Survey of Psychiatric Morbidity. British Journal of Psychiatry. 2004; 185:220–226. [PubMed: 15339826]

Belanoff JK, Kalehzan M, Sund B, Fleming Ficek SK, Schatzberg AF. Cortisol activity and cognitive changes in psychotic major depression. American Journal of Psychiatry. 2001; 158:1612–1616. [PubMed: 11578992]

Bifulco A, Bernazzani O, Moran PM, Jacobs C. The childhood experience of care and abuse questionnaire (CECA.Q): validation in a community series. British Journal of Clinical Psychology. 2005; 44:563–581. [PubMed: 16368034]

Brickman AM, Buchsbaum MS, Bloom R, Bokhoven P, Paul-Odouard R, Haznedar MM, Dahlman KL, Hazlett EA, Aronowitz J, Heath D, Shihabuddin L. Neuropsychological functioning in first-break, never-medicated adolescents with psychosis. Journal of Nervous and Mental Diseases. 2004; 192:615–622.

Brugha TS, Cragg D. The List of Threatening Experiences: the reliability and validity of a brief life events questionnaire. Acta Psychiatrica Scandinavica. 1990; 82:77–81. [PubMed: 2399824]

Brunner R, Schaefer D, Hess K, Parzer P, Resch F, Schwab S. Effect of high-dose cortisol on memory functions. Annals of the New York Academy of Sciences. 2006; 1071:434–437. [PubMed: 16891593]

Buchanan TW, Kern S, Allen JS, Tranel D, Kirschbaum C. Circadian regulation of cortisol after hippocampal damage in humans. Biological Psychiatry. 2004; 56:651–656. [PubMed: 15522248]

Ceskova E, Kasparek T, Zourkova A, Prikryl R. Dexamethasone suppression test in first-episode schizophrenia. Neuroendocrinology Letters. 2006; 27:433–437. [PubMed: 16892008]

Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. Journal of Health and Social Behavior. 1983; 24:385–396. [PubMed: 6668417]

Copolov D, Velakoulis D, McGorry P, Carina M, Yung A, Rees S, Jackson G, Rehn A, Brewer W, Pantelis C. Neurobiological findings in early phase schizophrenia. Brain Research Review. 2000; 31:157–165.

Cowen PJ. Not fade away: the HPA axis and depression. Psychological Medicine. 2010; 40:1–4. [PubMed: 19335939]

Dazzan P, Lloyd T, Morgan KD, Zanelli J, Morgan C, Orr K, Hutchinson G, Fearon P, Allin M, Rifkin L, McGuire PK, Doody GA, Holloway J, Leff J, Harrison G, Jones PB, Murray RM. Neurological abnormalities and cognitive ability in first-episode psychosis. British Journal of Psychiatry. 2008; 193:197–202. [PubMed: 18757976]

Dazzan P, Morgan KD, Orr K, Hutchinson G, Chitnis X, Suckling J, Fearon P, McGuire PK, Mallett RM, Jones PB, Leff J, Murray RM. Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the AESOP study. Neuropsychopharmacology. 2005; 30:765–774. [PubMed: 15702141]

Dazzan P, Morgan KD, Orr KG, Hutchinson G, Chitnis X, Suckling J, Fearon P, Salvo J, McGuire PK, Mallett RM, Jones PB, Leff J, Murray RM. The structural brain correlates of neurological soft signs in AESOP first-episode psychoses study. Brain. 2004; 127:143–153. [PubMed: 14570821]

Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR, Handley R, Luzi S, Russo M, Paparelli A, Butt A, Stilo SA, Wiffen B, Powell J, Murray RM. High-potency cannabis and the risk of psychosis. British Journal of Psychiatry. 2009; 195:488–491. [PubMed: 19949195]

Fisher H, Morgan C, Dazzan P, Craig TK, Morgan K, Hutchinson G, Jones PB, Doody GA, Pariante C, McGuffin P, Murray RM, Leff J, Fearon P. Gender differences in the association between childhood abuse and psychosis. British Journal of Psychiatry. 2009a; 194:319–325. [PubMed: 19336782]

Fisher HL, Craig TK, Fearon P, Morgan K, Dazzan P, Lappin J, Hutchinson G, Doody GA, Jones PB, McGuffin P, Murray RM, Leff J, Morgan C. Reliability and comparability of psychosis patients' retrospective reports of childhood abuse. Schizophrenia Bulletin. 2009b Published online: 7 October 2009. doi:10.1093/schbul/sbp103.

Flashman LA, Green MF. Review of cognition and brain structure in schizophrenia: profiles, longitudinal course, and effects of treatment. Psychiatric Clinics of North America. 2004; 27:1–18. vii. [PubMed: 15062627]

Garner B, Pariante CM, Wood SJ, Velakoulis D, Phillips L, Soulsby B, Brewer WJ, Smith DJ, Dazzan P, Berger GE, Yung AR, van den Buuse M, Murray R, McGorry PD, Pantelis C. Pituitary volume predicts future transition to psychosis in individuals at ultra-high risk of developing psychosis. Biological Psychiatry. 2005; 58:417–423. [PubMed: 16026767]

Gau SS, Shang CY. Executive functions as endophenotypes in ADHD: evidence from the Cambridge Neuropsychological Test Battery (CANTAB). Journal of Child Psychology and Psychiatry. 2010 Published online: 18 January 2010. doi:10.1111/j.1469-7610.2010.02215.x.

Gianaros PJ, Jennings JR, Sheu LK, Greer PJ, Kuller LH, Matthews KA. Prospective reports of chronic life stress predict decreased grey matter volume in the hippocampus. NeuroImage. 2007; 35:795–803. [PubMed: 17275340]

Gomez RG, Fleming SH, Keller J, Flores B, Kenna H, DeBattista C, Solvason B, Schatzberg AF. The neuropsychological profile of psychotic major depression and its relation to cortisol. Biological Psychiatry. 2006; 60:472–478. [PubMed: 16483550]

Gunduz-Bruce H, Szeszko PR, Gueorguieva R, Ashtari M, Robinson DG, Kane JM, Bilder RM. Cortisol levels in relation to hippocampal sub-regions in subjects with first episode schizophrenia. Schizophrenia Research. 2007; 94:281–287. [PubMed: 17490857]

Halari R, Kumari V, Mehrotra R, Wheeler M, Hines M, Sharma T. The relationship of sex hormones and cortisol with cognitive functioning in schizophrenia. Journal of Psychopharmacology. 2004; 18:366–374. [PubMed: 15358980]

Heim C, Nemeroff CB. Neurobiology of early life stress: clinical studies. Seminars in Clinical Neuropsychiatry. 2002; 7:147–159. [PubMed: 11953939]

Horan WP, Ventura J, Nuechterlein KH, Subotnik KL, Hwang SS, Mintz J. Stressful life events in recent-onset schizophrenia: reduced frequencies and altered subjective appraisals. Schizophrenia Research. 2005; 75:363–374. [PubMed: 15885527]

Hsu FC, Garside MJ, Massey AE, Lister-Williams RH. Effects of a single dose of cortisol on the neural correlates of episodic memory and error processing in healthy volunteers. Psychopharmacology (Berlin). 2003; 167:431–442. [PubMed: 12684731]

Lee BK, Glass TA, McAtee MJ, Wand GS, Bandeen-Roche K, Bolla KI, Schwartz BS. Associations of salivary cortisol with cognitive function in the Baltimore memory study. Archives of General Psychiatry. 2007; 64:810–818. [PubMed: 17606815]

Loberg EM, Hugdahl K. Cannabis use and cognition in schizophrenia. Frontiers in Human Neuroscience. 2009; 3:53. [PubMed: 19956405]

Lupien SJ, Fiocco A, Wan N, Maheu F, Lord C, Schramek T, Tu MT. Stress hormones and human memory function across the lifespan. Psychoneuroendocrinology. 2005; 30:225–242. [PubMed: 15511597]

Lupien SJ, Maheu F, Tu M, Fiocco A, Schramek TE. The effects of stress and stress hormones on human cognition: implications for the field of brain and cognition. Brain and Cognition. 2007; 65:209–237. [PubMed: 17466428]

Lysaker PH, Meyer P, Evans JD, Marks KA. Neurocognitive and symptom correlates of self-reported childhood sexual abuse in schizophrenia spectrum disorders. Annals of Clinical Psychiatry. 2001; 13:89–92. [PubMed: 11534930]

McAllister-Williams RH, Rugg MD. Effects of repeated cortisol administration on brain potential correlates of episodic memory retrieval. Psychopharmacology (Berlin). 2002; 160:74–83. [PubMed: 11862376]

McGuffin P, Farmer A, Harvey I. A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Archives of General Psychiatry. 1991; 48:764–770. [PubMed: 1883262]

Mondelli V, Dazzan P, Hepgul N, Di Forti M, Aas M, D'Albenzio A, Di Nicola M, Fisher H, Handley R, Marques TR, Morgan C, Navari S, Taylor H, Papadopoulos A, Aitchison KJ, Murray RM, Pariante CM. Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: the role of stress and of antipsychotic treatment. Schizophrenia Research. 2010a; 116:234–242. [PubMed: 19751968]

Mondelli V, Pariante CM, Navari S, Aas M, D'Albenzio A, Di Forti M, Handley R, Hepgul N, Marques TR, Taylor H, Papadopoulos AS, Aitchison KJ, Murray RM, Dazzan P. Higher cortisol levels are associated with smaller left hippocampal volume in first-episode psychosis. Schizophrenia Research. 2010b Published online: 13 January 2010. doi:10.1016/j.schres.2009.12.021.

Morgan KD, Dazzan P, Orr KG, Hutchinson G, Chitnis X, Suckling J, Lythgoe D, Pollock SJ, Rossell S, Shapleske J, Fearon P, Morgan C, David A, McGuire PK, Jones PB, Leff J, Murray RM. Grey matter abnormalities in first-episode schizophrenia and affective psychosis. British Journal of Psychiatry. Supplement. 2007; 51:s111–s116. [PubMed: 18055926]

Morrens M, Krabbendam L, Bak M, Delespaul P, Mengelers R, Sabbe B, Hulstijn W, van Os J, Myin-Germeys I. The relationship between cognitive dysfunction and stress sensitivity in schizophrenia: a replication study. Social Psychiatry and Psychiatric Epidemiology. 2007; 42:284–287. [PubMed: 17334897]

Myin-Germeys I, Delespaul P, van Os J. Behavioural sensitization to daily life stress in psychosis. Psychological Medicine. 2005; 35:733–741. [PubMed: 15918350]

Myin-Germeys I, Krabbendam L, Jolles J, Delespaul PA, van Os J. Are cognitive impairments associated with sensitivity to stress in schizophrenia? An experience sampling study. American Journal of Psychiatry. 2002; 159:443–449. [PubMed: 11870009]

Myin-Germeys I, van Os J, Schwartz JE, Stone AA, Delespaul PA. Emotional reactivity to daily life stress in psychosis. Archives of General Psychiatry. 2001; 58:1137–1144. [PubMed: 11735842]

Nelson, HE.; Willison, J. National Adult Reading Test (NART): Test Manual. 2nd edn.. NFER Nelson; Windsor: 1991.

Newcomer JW, Craft S, Askins K, Hershey T, Bardgett ME, Csernansky JG, Gagliardi AE, Vogler G. Glucocorticoid interactions with memory function in schizophrenia. Psychoneuroendocrinology. 1998; 23:65–72. [PubMed: 9618753]

Newcomer JW, Craft S, Hershey T, Askins K, Bardgett ME. Glucocorticoid-induced impairment in declarative memory performance in adult humans. Journal of Neuroscience. 1994; 14:2047–2053. [PubMed: 8198631]

Pariante CM, Dazzan P, Danese A, Morgan KD, Brudaglio F, Morgan C, Fearon P, Orr K, Hutchinson G, Pantelis C, Velakoulis D, Jones PB, Leff J, Murray RM. Increased pituitary volume in antipsychotic-free and antipsychotic-treated patients of the AESOP first-onset psychosis study. Neuropsychopharmacology. 2005; 30:1923–1931. [PubMed: 15956995]

Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends in Neuroscience. 2008; 31:464–468.

Pariante CM, Vassilopoulou K, Velakoulis D, Phillips L, Soulsby B, Wood SJ, Brewer W, Smith DJ, Dazzan P, Yung AR, Zervas IM, Christodoulou GN, Murray R, McGorry PD, Pantelis C. Pituitary volume in psychosis. British Journal of Psychiatry. 2004; 185:5–10. [PubMed: 15231549]

Perez CM, Widom CS. Childhood victimization and long-term intellectual and academic outcomes. Child Abuse and Neglect. 1994; 18:617–633. [PubMed: 7953902]

Porter RJ, Gallagher P, Thompson JM, Young AH. Neurocognitive impairment in drug-free patients with major depressive disorder. British Journal of Psychiatry. 2003; 182:214–220. [PubMed: 12611784]

Read J, van Os J, Morrison AP, Ross CA. Childhood trauma, psychosis and schizophrenia: a literature review with theoretical and clinical implications. Acta Psychiatrica Scandinavica. 2005; 112:330–350. [PubMed: 16223421]

Reichenberg A, Harvey PD. Neuropsychological impairments in schizophrenia: integration of performance-based and brain imaging findings. Psychological Bulletin. 2007; 133:833–858. [PubMed: 17723032]

Ringen PA, Vaskinn A, Sundet K, Engh JA, Jonsdottir H, Simonsen C, Friis S, Opjordsmoen S, Melle I, Andreassen OA. Opposite relationships between cannabis use and neurocognitive functioning in bipolar disorder and schizophrenia. Psychological Medicine. 2009 Published online: 6 November 2009. doi:10.1017/S0033291709991620.

Ryan MC, Sharifi N, Condren R, Thakore JH. Evidence of basal pituitary-adrenal overactivity in first episode, drug naive patients with schizophrenia. Psychoneuroendocrinology. 2004; 29:1065–1070. [PubMed: 15219658]

Saffer D, Metcalfe M, Coppen A. Abnormal dexamethasone suppression test in type II schizophrenia. British Journal of Psychiatry. 1985; 147:721–723. [PubMed: 3830336]

Sandstrom A, Rhodin IN, Lundberg M, Olsson T, Nyberg L. Impaired cognitive performance in patients with chronic burnout syndrome. Biological Psychology. 2005; 69:271–279. [PubMed: 15925030]

Schenkel LS, Spaulding WD, DiLillo D, Silverstein SM. Histories of childhood maltreatment in schizophrenia: relationships with premorbid functioning, symptomatology, and cognitive deficits. Schizophrenia Research. 2005; 76:273–286. [PubMed: 15949659]

Suzuki M, Konno C, Furihata R, Osaki K, Uchiyama M. Insomnia associated with psychiatric disorders [in Japanese]. Nippon Rinsho. 2009; 67:1507–1512. [PubMed: 19768932]

Szeszko PR, Betensky JD, Mentschel C, Gunduz-Bruce H, Lencz T, Ashtari M, Malhotra AK, Bilder RM. Increased stress and smaller anterior hippocampal volume. Neuroreport. 2006; 17:1825–1828. [PubMed: 17164672]

Thornberry TP, Ireland TO, Smith CA. The importance of timing: the varying impact of childhood and adolescent maltreatment on multiple problem outcomes. Developmental Psychopathology. 2001; 13:957–979.

Walder DJ, Walker EF, Lewine RJ. Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia. Biological Psychiatry. 2000; 48:1121–1132. [PubMed: 11137052]

Weber DL, Clark CR, McFarlane AC, Moores KA, Morris P, Egan GF. Abnormal frontal and parietal activity during working memory updating in post-traumatic stress disorder. Psychiatry Research. 2005; 140:27–44. [PubMed: 16202566]

Wechsler, D. WAIS-III Administration and Scoring Manual. The Psychological Corporation; San Antonio, TX: 1997a.

Wechsler, D. WMS-III Technical Manual. The Psychological Corporation; San Antonio, TX: 1997b.

WHO. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. World Health Organization; Geneva: 1992.

Widom CS, Czaja SJ, Dutton MA. Childhood victimization and lifetime revictimization. Child Abuse and Neglect. 2008; 32:785–796. [PubMed: 18760474]

Wolf OT. HPA axis and memory. Best Practice and Research Clinical Endocrinology and Metabolism. 2003; 17:287–299. [PubMed: 12787553]

Yehuda R. Neuroendocrine aspects of PTSD. Handbook of Experimental Pharmacology. 2005; 169:371–403. [PubMed: 16594265]

Young AH, Gallagher P, Watson S, Del-Estal D, Owen BM, Ferrier IN. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology. 2004; 29:1538–1545. [PubMed: 15127079]

Zanelli J, Reichenberg A, Morgan K, Fearon P, Kravariti E, Dazzan P, Morgan C, Zanelli C, Demjaha A, Jones PB, Doody GA, Kapur S, Murray RM. Specific and generalized neuropsychological deficits: a comparison of patients with various first-episode psychosis presentations. American Journal of Psychiatry. 2010; 167:78–85. [PubMed: 19952077]

Fig. 1.
Scatter plot and linear regression of cortisol awakening response and *z* scores of (*a*) verbal memory and (*b*) processing speed domains, in patients. Significant positive correlations were observed for both verbal memory (*r*=0.48, *p*=0.019) and processing speed (*r*=0.38, *p*=0.048).

Fig. 2.
Z scores (means and standard deviations) of the individual cognitive domains in subjects divided into (*a*) those below and above the median of the cortisol awakening response and (*b*) those below and above the median of cortisol secretion during the day. The individual cognitive tests were grouped into six domains: Verbal memory; Non-verbal memory; Executive function perception; Visuospatial abilities; and Processing speed. Scores on each cognitive domain were calculated as the mean of standard (*z*) scores of the individual tests. *Z* scores were based on the mean and standard deviation of the control sample. (*a*) Within patients, the group with the cortisol awakening response below the median (i.e. more blunted and hence more abnormal) did worse on all cognitive domain, reaching statistical significance for verbal memory and processing speed, and trend significance for perception and visuospatial abilities. No differences were observed between controls with a high and with a low cortisol awakening response in any cognitive domains. (*b*) No differences were found in cognitive function between subjects with low and high cortisol levels during the day, in either patients or controls. * $p<0.05$.

Table 1

Sociodemographic and clinical characteristics of patients with first-episode psychosis (FEP) and gender- and age-matched controls

	Patients	Controls	t or χ^2	df	p value
Total number	30	26			
Age (years)	30.1±7.2	27.5±4.8	1.6	54	0.12
Gender					
Male/female	20/10 (68/32)	18/8 (69/31)	0.04	1	0.84
Education[a]			25.8	4	<0.001
No education	3 (10.0)	-			
GCSEs	9 (30.0)	-			
A-level	6 (20.0)	3 (11.5)			
Vocational	8 (26.7)	3 (11.5)			
University	4 (13.3)	20 (26.9)			
Ethnicity			5.3	2	0.07
White British	8 (26.7)	10 (38.5)			
Black	17 (56.7)	7 (26.9)			
Other	5 (16.7)	9 (34.6)			
Lifetime frequency of cannabis use			7.6	3	0.054
No use	11 (36.7)	14 (53.8)			
<10 times	1 (3.3)	5 (19.2)			
<100 times	3 (10.0)	1 (3.8)			
>100 times	15 (50.0)	6 (23.1)			
CECA-Q: severe trauma present	19 (63)	11 (42)	2.5	1	0.12
Cortisol awakening response (AUCi)	80.02±257.4	235.5±253.8	2.3	54	0.027
Cortisol during the day (AUC)	95.40±57.6	73.73±17.7	−1.9	50	0.09
Perceived Stress Scale	18.5±7.7	11.7±6.3	3.6	53	0.001
Brief life events questionnaire	2.0±1.7	0.9±1.2	−2.8	53	0.007

CECA-Q, Childhood Experience of Care and Abuse Questionnaire; AUC, Area Under the Curve; AUCi, increase in AUC; df, degrees of freedom.

Values given as n (%) or mean±standard deviation.

[a]The General Certificate of Secondary Education (GCSE) is taken at the final year of compulsory high-school education; A-levels are studied typically between the ages of 16 and 18 in preparation for university; a vocational degree prepares learners for jobs that are based on manual or practical activities, traditionally non-academic and related to a specific trade or occupation.

Table 2

Comparisons of individual task scores between patients and controls, with or without adjustment for education, ethnicity and cannabis use

	Patients Mean±s.d.	Controls Mean±s.d.	Statistics f, df, p value
General cognitive function			
WAIS Full-scale IQ	87.3±18.3	108.4±17.1	15.0, 1, <0.001 *
	88.9 ± 4.2	106.8 ± 4.2	7.6, 1, 0.009 *
NART Pre-morbid IQ	96.2±7.8	103.9±6.3	13.5, 1, 0.001 *
	91.0 ± 2.1	102.6 ± 2.0	13.2, 1, 0.001 *
Verbal memory			
WMS-III Logical Memory Immediate Recall	22.5±7.7	39.5±10.5	39.7, 1, <0.001 *
	22.6±2.2	39.3±2.2	22.8, 1, <0.001 *
WMS-III Logical Memory Delayed Recall	11.9±6.5	24.9±7.2	42.1, 1, <0.001 *
	11.6±1.7	25.1±1.7	26.1, 1, <0.001 *
WMS-III Recognition	21.0±4.2	26.4±2.4	28.6, 1, <0.001 *
	20.8 ± 0.8	26.6 ± 0.8	19.8, 1, <0.001 *
Non-verbal memory			
WMS-III Visual Reproduction Immediate Recall	79.9±18.3	89.4±7.8	5.7, 1, 0.02 *
	82.6 ± 3.2	86.5 ± 3.4	0.5, 1, 0.46
WMS-III Visual Reproduction Delayed Recall	48.0±26.2	68.0±22.1	8.8, 1, 0.005 *
	52.3±5.5	63.4 ± 5.8	1.5, 1, 0.22
WMS-III Visual Percentage Retention	56.7±25.9	75.5±22.5	7.8, 1, 0.008 *
	61.0± 5.5	70.8 ± 5.8	1.2, 1, 0.28
Executive function			
Trail B	139.4±84.8	66.4±19.8	18.3, 1, <0.001 *
	131.0± 14.0	74.5±13.7	6.7, 1, 0.013 *
Spatial Working Memory (CANTAB) Strategy Raw Score	35.8±5.3	30.0±6.2	12.7, 1, 0.001 *
	34.9 ± 1.3	31.0 ± 1.4	3.3, 1, 0.075
Spatial Working Memory (CANTAB) Between Errors Raw Score	45.7±23.4	24.3±22.3	10.9, 1, 0.002 *

	Patients Mean±s.D.	Controls Mean±s.D.	Statistics *f*, df, *p* value
Perception and visuospatial abilities	*42.0 ± 5.1*	*28.6 ± 5.6*	*2.5, 1, 0.12*
WAIS-III Block Design	28.5±14.8	44.9±13.0	*19.0, 1, <0.001* *
	30.8 ± 2.9	*42.2 ± 3.2*	*5.6, 1, 0.022* *
WAIS-III Matrix Reasoning	12.7±5.9	17.7±4.5	*11.4, 1, 0.001* *
	13.7 ± 1.2	*16.7 ± 1.2*	*2.4, 1, 0.13*
Processing speed			
WAIS-III Digit Symbol Coding	47.9±17.6	68.2±23.2	*8.9, 1, 0.005* *
	50.2 ± 4.6	*65.0 ± 5.7*	*3.4, 1, 0.076*
Trail A	58.4±27.9	34.8±11.1	*16.3, 1, <0.001* *
	52.9 ± 4.5	*40.8 ± 4.7*	*2.7, 1, 0.1*
General knowledge			
WAIS-III Information	13.7±6.1	18.8±4.9	*8.7, 1, 0.005* *
	13.7 ± 1.3	*18.7 ± 1.3*	*6.2, 1, 0.017* *

WAIS, Wechsler Adult Intelligence Scale; NART, National Adult Reading Test; WMS, Wechsler Memory Scale; CANTAB, Cambridge Neuropsychological Test Automated Battery; s.D., standard deviation; df, degrees of freedom.

Estimated values and statistics after co-varying for education, ethnicities and cannabis use are shown in italics.

*
Statistically significant difference (*p*<0.05).

Table 3

Spearman's correlations (r values) between cortisol and cognitive domains

	Cortisol awakening response		Cortisol during the day	
	Patients	**Controls**	**Patients**	**Controls**
Verbal memory	0.48[b]	−0.09	0.10	0.30
Non-verbal memory	0.35[a]	0.16	−0.24	0.12
Executive function	0.21	−0.04	−0.19	0.11
Processing speed	0.38[b]	0.12	−0.27	0.32
Perception and visuospatial abilities	0.24	0.11	−0.29	0.17
Verbal subtest, general knowledge	−0.03	0.36	0.40[a]	0.40[a]

[a]
p<0.10

[b]
p<0.05

[c]
p<0.01.

Table 4

Spearman's correlations (r values) between psychosocial stressors and specific cognitive domains

	Perceived stress scale		Recent life events (Brief life events questionnaire)		Childhood trauma (CECA-Q)	
	Patients	Controls	Patients	Controls	Patients	Controls
Verbal memory	−0.19	−0.35[a]	0.18	−0.28	0.11	−0.03
Non-verbal memory	0.21	−0.15	0.18	−0.12	0.18	−0.23
Executive function	−0.001	−0.43[b]	0.11	−0.40[b]	0.02	0.11
Processing speed	0.04	−0.17	−0.11	−0.11	0.02	−0.11
Perception and visuospatial abilities	−0.16	−0.55[c]	−0.05	−0.40[b]	−0.16	0.13
Verbal subtest, general knowledge	−0.26	−0.52[b]	0.24	−0.19	0.14	−0.05

CECA-Q, Childhood Experience of Care and Abuse Questionnaire.

[a] p<0.10

[b] p<0.05

[c] p<0.01.